Peptonic Medical AB (Sweden) entered a tech transfer agreement with Orion Contract Manufacturing Organisation (CMO) (Finland) to prepare for the commercial manufacture of VagiVital – a product that Peptonic plans to launch.
Peptonic Medical is an innovative Swedish development company. VagiVital® is a trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy. The pipeline of Peptonic Medical also includes Vagitocin, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin is on hold pending additional data on i.a. the mechanism of action.
Orion is a globally operating Finnish pharmaceutical company. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler pulmonary drugs.
Orion Corporation, headquartered in Espoo, Finland, is pleased that Peptonic chose Orion as their CMO. Under the agreement, the two companies will exchange information and collaborate to prepare for the commercial manufacture of VagiVita – a product that Peptonic plans to launch in 2018. In addition to the tech transfer agreement, the companies have signed a terms sheet for a final agreement regarding the commercial manufacture of VagiVital.